Control of bacterial infection-induced inflammatory responses is one of the effective therapeutic approaches of periodontal diseases. Natural products such as lipid mediators and metabolites from microorganisms have been used for decreasing inflammation. We previously reported that (þ)-terrein inhibited activation of STAT3 and ERK1/2 in interleukin-6 (IL-6) signaling cascade, leading to prevent vascular endothelial growth factor (VEGF) secretion in human gingival fibroblasts (HGFs). However, little is still known about the role of (þ)-terrein on inflammatory responses. In this study, we provided the possibility of novel action that (þ)-terrein inhibits activation of Janus-activated kinase 1 (JAK1), which has a central function in IL-6 signaling cascade, and alters expression of mRNAs and proteins induced by IL-6/soluble IL-6 receptor (sIL-6R) stimulation in HGFs. First, we performed PCR array to examine IL-6/sIL-6R-induced mRNA expression, and then expression of mRNA and protein of colony stimulating factor-1 (CSF1) and VEGF were clearly determined by quantitative RT-PCR and ELISA, respectively. Treatment with (þ)-terrein suppressed expression of mRNA and protein of CSF1 and VEGF by IL-6/sIL-6R stimulation. Next, to test the effect of (þ)-terrein on IL-6/sIL-6R signaling cascade, we demonstrated whether (þ)-terrein affects phosphorylation of JAK1 and its downstream proteins, Akt and SHP-2. Western blotting revealed that (þ)-terrein inhibited IL-6/sIL-6R-induced phosphorylation of JAK1, Akt, and SHP-2. Therefore, (þ)-terrein suppresses IL-6/sIL-6R-induced expression of CSF1 and VEGF via inhibition of JAK1, Akt, and SHP-2. Based on our results, we suggest that (þ)-terrein is a candidate compound for anti-inflammatory effect associated with IL-6 signaling.
Introduction
Periodontitis is a chronic inflammatory disease characterized by the destruction of periodontal tissue and loss of alveolar bones [1] , and caused by inflammationassociated dysbacteriosis of commensal microbiota; however, the temporal sequence of and interplay between specific bacteria and inflammation is not well understood [2] . Mechanical debridement, e.g., scaling and root planning and/or flap surgery, has long been the standard protocol for treating moderate-to-severe periodontitis [3] .
Removal of subgingival plaque and calculus is sufficient to reduce bacteriainduced host inflammatory response regulated by multiple inflammatory cytokines, such as tumor necrosis factor-a, interleukin (IL)-1b and IL-6, and to suppress periodontal tissue destruction. However, subgingival debridement has limitations because of anatomical variations, including existing root furcation involvement, which results in the incomplete removal of diseased lesions [4] . Irrespective of the completeness of debridement, residual bacteria grow back gradually after mechanical treatment in the absence of additional treatment or maintenance, resulting in the recurrence of disease-associated inflammation [5] . Antibacterial therapy improves clinical symptoms but is associated with antibiotic resistance and other side effects [6] . Therefore, novel host-modulation treatment approach instead of antibiotics is required.
IL-6 is one of the most important pro-inflammatory cytokines and exerts various biological effects and plays an important role in the progression of inflammatory diseases including periodontitis [12, 13] . The IL-6/soluble IL-6 receptor (sIL-6R) complex activates glycoprotein 130 (gp130) that, in turn, up-regulates Janus-activated kinase (JAK)/signal transducers and activators of transcription-3 (STAT3)
signaling, Ras/mitogen activator of protein kinase (MAPK) signaling and phosphoinositide 3-kinase (PI3k)/Akt signaling pathway. Blocking IL-6 cascade was recently shown to have therapeutic effects in several autoimmune and inflammatory disease models such as rheumatoid arthritis [44] and periodontitis [45] . Thus, control of IL-6 signaling is lead to control of chronic inflammation [12] .
(þ)-Terrein was isolated from Aspergillus terreus as a secondary bioactive fungal metabolite by Raistrick and Smith in 1935 [7] . (þ)-Terrein exerts various biological effects, including antibacterial effect [8] , inhibition of angiogenin secretion in prostate cancer cells [9] , and modulation of pulpal inflammation [10] . In our previous study, we established the synthesis of (þ)-terrein, and reported that (þ)-terrein inhibited IL-6/sIL-6R-induced phosphorylation of STAT3 and extracellular signalregulated kinase 1/2 (ERK1/2) in human gingival fibroblasts (HGFs), resulting in suppression of vascular endothelial growth factor (VEGF) secretion [11] . Therefore, we think that (þ)-terrein might be a useful tool to regulate IL-6 signaling and to suppress IL-6-associated inflammatory disease progression [11] . However, the antiinflammatory effects of (þ)-terrein and the underlying functional mechanism are unclear.
The present study examined the effect of (þ)-terrein on IL-6/sIL-6R-induced protein secretion using PCR array and determined the target molecules of (þ)-terrein in the IL-6 signaling pathway in HGFs. Our results can be used to establish a novel hostmodulation treatment approach by using (þ)-terrein for preventing and treating inflammatory diseases, including periodontitis.
Material and methods

Reagents
Synthetic (þ)-terrein was prepared from dimethyl L-tartrate, as described previously [11] . Recombinant human IL-6 and sIL-6R were purchased from R&D Systems (Minneapolis, MN). Rabbit anti-phosphorylated Akt and Src homology 2 domaincontaining phosphatase-2 (SHP-2) polyclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA). Rabbit anti-phosphorylated Janus-activated kinase 1 (JAK1) polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-b-actin monoclonal antibody was obtained from Sigma (St. Louis, MO). JAK1/2 inhibitor, baricitinib, was obtained from Chemscene (Monmouth Junction, NJ).
Cell culture
HGFs were generated as described previously [14] and were cultured in DMEM sIL-6R (50 ng/ml each) for specific duration. Cytotoxity of (þ)-terrein on HGFs has been reported previously [11] , and less than 10 mM of (þ)-terrein has no effect on cell viability in HGFs.
PCR array and quantitative reverse transcription-PCR
After stimulation for 12 h, total RNA was extracted from the cells using RNeasy Ò Mini Kit (Qiagen, Hilden, Germany), and DNA contamination was removed using BMP2  BMP3  BMP4  BMP5  BMP6  BMP7  BMP8B  CECR1   CLC  CSF1  CSF2  CSF3  CSPG5  CXCL1  DKK1  ERAP1  EREG  FGF1  FGF11  FGF13   FGF14  FGF17  FGF19  FGF2  FGF22  FGF23  FGF5  FGF6  FGF7  FGF9  FIGF  GDF10   GDF11  GDNF  GPI  HBEGF  IGF1  IGF2  IL10  IL11  IL12B  IL18  IL1A  IL1B   IL2  IL3  IL4  INHA  INHBA  INHBB  JAG1  JAG2  LEFTY1  LEFTY2  LIF  LTBP4   MDK  MSTN  NDP  NGF  NODAL  NRG1  NRG2  NRG3  NRTN  NTF3  OSGIN1  PDGFC   PGF  PSPN  PTN  SLCO1A2  SPP1  TDGF1  TGFB1  THPO  TNNT1  TYMP  VEGFA  VEGFC   ACTB  B2M  GAPDH  HPRT1  RPLP0  HGDC  RTC  RTC  RTC  PPC reticulum aminopeptidase 1 (ERAP1)] were designed using Primer3 Plus (http:// primer3plus.com/cgi-bin/dev/primer3plus.cgi) and NCBI Primer-BLAST (https:// www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR primer sets used in this study are listed in Table 2 . Quantitative PCR was performed to amplify up to 1 ng cDNA by using specific primers. Each sample was examined in a 10 ml reaction mixture by using SYBR Green PCR Master Mix (Thermo Fisher Scientific) and 7300
Real-Time PCR System (Thermo Fisher Scientific). Ratios of mRNA levels to control values were calculated using the DCt method (2 ÀDDCt ). All data were normalized using the mRNA level of the housekeeping gene GAPDH. PCR conditions used are as follows: hold for 10 min at 95 C, followed by 40 cycles of 15 s at 95 C and 60 s at 60 C.
Enzyme-linked immunosorbent assay
After stimulation for 24 h, culture supernatant was collected and stored at -80 C for further use. VEGF and CSF1 levels were measured using sandwich enzyme-linked Table 2 . Genes and their respective primer sequence and amplicon size used in this study.
Gene primer sequence Amplicon size (bp)
immunosorbent assay (ELISA) kits containing human anti-VEGF and anti-CSF1 antibodies (R&D Systems), according to the manufacturer's instructions. 
Western blotting
Statistical analysis
Experimental results are presented as mean AE SD. Multiple groups were compared using one-way ANOVA/Scheffe's test, and p < 0.05 was considered statistically significant. 
Expression of mRNA and protein for CSF1 and VEGF was determined by quantitative RT-PCR and ELISA
Changes in the expression levels six genes (VEGF-A, BDNF, DKK1, BMP1, ERAP1
and CSF1) observed in the PCR arrays were validated by performing quantitative RT-PCR by using mRNA obtained from the same samples as those used for performing PCR arrays (Fig. 1) . Results of quantitative RT-PCR showed a correlation between VEGF-A and CSF1 expression (p < 0.05; Fig. 1A and B) . However, quantitative RT-PCR did not show a correlation of other 4 genes (BDNF, DKK1, BMP1, and ERAP1) expression (Fig. 1CeF) . In addition, we examined the secretion of VEGF-A and CSF1 into the culture supernatant by performing ELISA. We demonstrated that (þ)-terrein suppresses IL-6/sIL-6R-induced expression of VEGF-A and ) were cultured until they reached subconfluence. Next, the cells were pretreated with (þ)-terrein (10 mM) for 30 min, followed by stimulation with IL-6/sIL-6R (50 ng/mL each) for 12 h. Total RNA was extracted, as described in Materials and Methods, and was analyzed by performing quantitative RT-PCR with specific primers shown in Table 2 . GAPDH was used as an internal control. Data are expressed as mean AE SD and are representative of three independent experiments; *p < 0.05 (ANOVA/Scheffe's test).
CSF1 (p < 0.05; Fig. 2A and B) . On the other hand, JAK1/2 inhibitor, baricitinib, suppressed IL-6/sIL-6R-induced CSF1 secretion as well as (þ)-terrein (p < 0.05; Fig. 2C ).
(D)-Terrein suppressed IL-6/sIL-6R-induced JAK1 phosphorylation
JAK1 is the upstream kinase of them in IL-6 signaling pathway, and hence we examined whether (þ)-terrein affects phosphorylation of JAK1 induced by IL-6/sIL-6R stimulation. HGFs were treated with or without (þ)-terrein at 10 mM for 30 min, (Fig. 3A) . Furthermore, we found that Akt and SHP-2, which are downstream molecules of JAK1 in IL-6 signaling pathway, were markedly reduced their phosphorylation by treatment with (þ)-terrein ( Fig. 3B and C) . These results indicated that (þ)-terrein might have an inhibitory effect on IL-6/sIL-6R-induced cellular responses via JAK1 inhibition.
Discussion
In the present study, we found that treatment with (þ)-terrein suppressed IL-6/sIL-6R-induced secretion of CSF1 and phosphorylation of JAK1, a JAK family protein present just below the cell membrane in HGFs. Together, these findings suggest that (þ)-terrein may play an important role by suppressing JAK1 phosphorylation to regulate IL-6 signaling and CSF1-and VEGF-induced inflammation in HGFs (Fig. 4) .
Recent studies have shown that susceptibility to and pathogenesis of periodontitis are mediated by host immune response [16, 17] . Patients with severe periodontitis exhibit hyper-inflammation, which is characterized by multiple cytokines production [18] and oxidative stress [19] . These host-immune response markers also can be used to predict diseases progression [20] . Previous animal and clinical studies assessing the regulation of host inflammatory response have shown that cyclooxygenase inhibitors suppress disease progression without modifying bacterial composition [21, 22] . However, long-term use of cyclooxygenase inhibitors is associated with serious side effects such as increased risk of gastrointestinal tract bleeding and cardiovascular diseases [23] that discourage the persistent clinical use of these inhibitors for treating periodontitis. In addition, periodontitis is associated with increased prevalence of several systemic diseases such as diabetes and cardiovascular disease as well as with preterm birth [24, 25] . Therefore, there is a critical need to develop reasonable and safe host modulation treatments for preventing and treating periodontitis.
IL-6 is an important proinflammatory cytokine that performs multiple functions in various cell types, and blockade of IL-6 signaling is an effective strategy for managing chronic inflammatory diseases and cancer progression [26] . We previously showed that (þ)-terrein suppressed VEGF secretion by inhibiting phosphorylation of STAT3 and ERK1/2 [11] , suggesting that synthetic (þ)-terrein-induced inhibition of IL-6 signaling is a novel approach for treating IL-6-associated inflammatory diseases. In addition, (þ)-terrein therapy might be suggested to be more economical and convenient than conventional anti-IL-6 antibody therapies. However, little is known about the effects of (þ)-terrein on IL-6/sIL-6R-induced protein synthesis and target molecules of (þ)-terrein. We first examined the effect of (þ)-terrein on IL-6/ sIL-6R-induced gene expression pattern by using PCR arrays (Table 3) . PCR array data showed that (þ)-terrein did not exert significant effects on gene expression pattern, indicating that (þ)-terrein is not a cytotoxic compound. However, (þ)-terrein suppressed IL-6/sIL-6R-induced expression of several mRNAs, including VEGF mRNA (Table 3) . Moreover, we found that (þ)-terrein significantly suppressed IL-6/sIL-6R-induced CSF1 and VEGF mRNA and protein expression ( Figs. 1 and 2 ).
CSF1, also known as macrophage colony-stimulating factor (M-CSF), is a secreted cytokine that performs various biological functions, including differentiation of hematopoietic stem cells into macrophages [27, 28] and differentiation of precursor cells into osteoclasts [29] . In mice lipopolysaccharide-induced periodontitis model, the expression M-CSF is enhanced in inflamed periodontal tissue [30] , indicate that CSF1 (M-CSF) is one of key players to increase osteoclastogenesis and alveolar bone resorption [31, 32] . In addition, macrophages induce immune responses by promoting foreign body phagocytosis, antigen presentation, and proinflammatory cytokine production. Remaining of infection source, such as subgingival calculus, causes cytokine network-centered endless negative cycle of chronic inflammation. Thus, (þ)-terrein-induced suppression of CSF1 secretion can abolish this negative cycle regulated by IL-6. Previous studies have shown that (þ)-terrein performs various biological functions, including intracellular signaling. In mouse melanocytes, treatment with 10e100 mM (þ)-terrein inhibits melanogenesis by reducing tyrosinase production through MAPK activation [33] . (þ)-Terrein reduces intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in dental pulp cells by blocking nuclear factor-kappa B (NF-kB) and Akt activation [10] . We previously reported that treatment with 10 mM synthetic (þ)-terrein suppressed VEGF secretion in HGFs by blocking STAT3 and ERK1/2 activation [11] . (þ)-Terrein promotes the differentiation of osteoblast-like MC-3T3E1 cells grown on a titanium surface by blocking the nuclear translocation of NF-kB [34] .
Moreover, (þ)-terrein exerts antioxidant effect by upregulating MAPK and focal adhesion kinase activity [34] . In epidermal keratinocytes, (þ)-terrein suppresses MAPK activation and cell proliferation without exerting cytotoxicity [35] . Thus, the results of these studies indicate that (þ)-terrein suppress intracellular signaling molecules, including MAPKs, STAT3, Akt, and NF-kB. However, precise targets of (þ)-terrein have not been reported to date. The present study is the first to show that (þ)-terrein suppresses phosphorylation of JAK1, the most upstream molecule in the IL-6 signaling pathway, in the cytosol (Fig. 3A) .
JAK1 belongs to JAK protein family, which includes JAK1, JAK2, JAK3, and tyrosine kinase 2. JAK family proteins are located just below the cell membrane and are involved in signaling induced by several cytokines [36] , including IL-2, IL-4, IL-6, interferon-a (IFN-a) , IFN-b, tumor necrosis factor-a, and leukemia inhibitory factor [37] . An abnormality in JAK1 induces rheumatoid arthritis [38] , atopic diathesis [39] , and hematologic malignancy [40] . Furthermore, absence of JAK1 is associated with a disorder in neural stem cell differentiation [41] , and diseased activity of JAK2
is associated with mutations in hematopoietic stem cells [42] . Recently, JAK inhibitor is focused on and developed for those intractable diseases [43] . JAK inhibitor has a lot of significant features, being available for oral administration owing to low-molecular compound like (þ)-terrein, short half-life, and low cost compared to biological products. The results in the present study provide new insights on the potential of (þ)-terrein to inhibit JAK1. However, additional studies should be performed to examine how to interact with (þ)-terrein and JAK1 in cytosol, and the effect of (þ)-terrein on other JAK family proteins like JAK2 for future experiments. In addition, the side effects of (þ)-terrein like immunosuppression also need to be considered as well as other JAK inhibitors.
Conclusion
In summary, we performed a comprehensive analysis to show that (þ)-terrein suppressed IL-6/sIL-6R-induced CSF1 secretion in HGFs. Moreover, we identified JAK1 as a putative target molecule of (þ)-terrein in HGFs. These data indicate that (þ)-terrein might be useful for regulating IL-6 signaling in chronic inflammatory diseases including periodontitis, and be able to be applied to not only antiinflammatory but also variety of fields by regulating JAK1 phosphorylation.
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